Identify non-invasive biomarkers

Biomarkers that can help diagnose, predict outcomes, or monitor therapeutic responses in human diseases are essential for the development and clinical assessment of new drugs. In many cases, this currently relies on invasive sampling (e.g. tissue biopsies) or expensive imaging procedures that require access to high-cost, access-constrained equipment and expert analysis. One important example is in neurological diseases, where even access to fluid biomarkers frequently involves lumbar puncture to obtain cerebrospinal fluid (CSF). Alzheimer’s Disease (AD) develops over several years prior to detection and mostly relies on CT/MRI imaging and invasive sampling of CSF for diagnosis.

A team from The Hong Kong University of Science and Technology used the Olink® Target platform to measure >1100 proteins in plasma samples from AD patients and controls, identifying over 400 differentially regulated proteins. Hierarchical clustering associated with a distinct biological process and unique cell-specific expression profiles identified 19 “hubs, 7 of which showed significant correlation to cognitive performance phenotypes, reflecting different AD endotypes. Performance analysis in discovery and validation cohorts of a profile composed of one representative protein from each of the 19 hubs achieved very high-accuracy AD classification with an AUC of 0.959.

20220725-Figure-3-Receiver-operator-characteristic-curve

Alzheimer’s Disease

Plasma proteomics identifies a 19-protein signature to classify Alzheimer’s Disease with an accuracy of ~96%.

Jiang Y, et al. (2021) Alzheimers & Dementia, DOI: 10.1002/alz.12369

Neurology

Developing a high-performance biomarker panel for Alzheimer’s Disease

Proteomics at the heart of multiomics strategies

Systems biology approaches addressing multiple molecular and cellular components are adding vital insights into the dynamic biology underlying human health and disease.

Hear from industry experts on how proteomics is changing the way we develop new drugs and study disease.

The power of proteomics in multiomic studies

Download the eBook, ‘Proteomics at the heart of multiomic studies’ to learn more about how this trend is the next step in advancing precision medicine.

2947

Biomarker assays

~881 million

Protein data points generated

1049

Publications listed on website

Contact us!